Breaking News, Collaborations & Alliances

AmyriAD Selects Societal CDMO to Support the Development of AD101

Societal will execute a range of clinical trial services to support the initiation of Phase 3 and Phase 4 clinical studies.

Author Image

By: Charlie Sternberg

Associate Editor

Societal CDMO Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, has been selected by AmyriAD Pharma to provide CDMO services to support the ongoing clinical development of AD101.   The compound, a novel T-type calcium channel modulator, is currently in clinical development for the treatment of Alzheimer’s disease (AD). AmyriAD has successfully completed Ph...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters